Valley Fever Awareness and Vaccine Development and Manufacturing Act of 2024

This bill establishes a federal coordinator within the Department of Health and Human Services to advance valley fever (coccidioidomycosis) vaccine development, licensing, and manufacturing by 2034. It requires a national strategy detailing scientific progress, funding needs, and regulatory pathways, with grants of $500,000-$2.5 million for vaccine development and $500,000-$5 million for manufacturing. The bill also creates a National Valley Fever Registry to collect non-identifiable case data and improve diagnosis, funded through $26 million in authorized appropriations. It directly affects researchers, vaccine manufacturers, patients in endemic regions (like the Southwest U.S.), and public health agencies coordinating vaccine efforts.